It is emblematic that IFN β, the first DMT to be approved for MS, is analogous of the endogenous IFN, which increases the activity of regulatory T cells and promotes an anti-inflammatory environment in the gut [35]. This evidence concerns the gene IFNA1 and myeloid sarcoma.